Evidence map›Paper›PMID 40507140›Full record

ReviewNutrients2025

Unveiling the Power of Bergamot: Beyond Lipid-Lowering Effects.

Myriam Carpenito, Federica Coletti, Saverio Muscoli, Lorenzo Guarino, Anna Di Cristo, Valeria Cammalleri, Simona Mega, Sara Emerenziani, Michele Cicala, Chiara Fanali and 2 more

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Bergamot (Food science & nutrition · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Myriam CarpenitoDepartment of Cardiovascular Sciences, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Rome, Italy.
Federica ColettiFondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
Saverio MuscoliDivision of Cardiology, Policlinico Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.ORCID 0000-0002-4037-7561
Lorenzo GuarinoFondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
Anna Di CristoDepartment of Cardiovascular Sciences, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Rome, Italy.
Valeria CammalleriFondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.ORCID 0000-0001-5374-8125
Simona MegaFondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.ORCID 0009-0009-0544-5651
Sara EmerenzianiGastroenterology Unit, Campus Bio-Medico University of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy.
Michele CicalaGastroenterology Unit, Campus Bio-Medico University of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy.ORCID 0000-0002-5370-2642
Chiara FanaliDepartment of Science and Technology for Sustainable Development and One Health, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy.
Gian Paolo UssiaDepartment of Cardiovascular Sciences, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Rome, Italy.ORCID 0000-0001-8849-3097
Francesco GrigioniDepartment of Cardiovascular Sciences, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dyslipidemia is a leading risk factor for cardiovascular diseases. Nutraceuticals for the management of dyslipidemia are gaining growing attention. Derived from food sources, they represent a promising adjunctive or alternative therapeutic option in specific clinical contexts, particularly in individuals with mild dyslipidemia or those who fail to achieve lipid targets despite optimal pharmacological treatment. Bergamot-alongside its lipid-lowering effects-has demonstrated multiple additional properties, including anti-inflammatory, antioxidant, and vascular benefits. While lipid effects are supported by several clinical studies, evidence for vascular and inflammatory pathways is based mainly on preclinical studies. This review summarizes the mechanisms of action and available clinical evidence and outlines potential indications for bergamot use in selected patient subgroups.

Indexed as

CitrusDietary SupplementsDyslipidemiasHypolipidemic AgentsPlant ExtractsAnimalsAnti-Inflammatory AgentsAntioxidantsCardiovascular DiseasesHumansAnti-Inflammatory AgentsAntioxidantsHypolipidemic AgentsPlant Extractsbergamotcardiovascular diseasesdyslipidemianutraceuticals

Identifiers

PMID40507140
PMCPMC12158049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.